Duodopa rejected for NHS use in Scotland

News

Author: Almaz OhenePublished: 11 January 2016

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

News image

The advanced Parkinson’s treatment Duodopa has been rejected for routine use on the NHS in Scotland, sparking concerns among charities and health professionals.

The Scottish Medicines Consortium (SMC) said it was unable to approve of Duodopa, due to questions raised over its cost-effectiveness.

Dr Alan MacDonald, vice chairman of SMC, said: “The Committee was unable to accept co-careldopa intestinal gel (Duodopa) for the routine treatment of advanced Parkinson’s disease because of uncertainty about the clinical benefits the medicine would provide for this patient group in relation to its cost.”

Duodopa, which can help to control the symptoms of advanced Parkinson’s when all other treatments have stopped working. The gel treatment is administered to the intestine via pump and a tube and requires the patient to undergo surgery – it is estimated to cost around £28,000-per-year per patient and was approved for use by the NHS in England in July 2015.

Go Back

Share this story

Comments


Related articles


forked wooden pedestrian walkway

sponsored article

PD in Practice

Could your subconscious mind affect your Parkinson’s treatment outcomes?

Drivers for decisions – new insights may help optimise treatment

READ MORE
White-Book-launch

PD in Practice

Campaigners publish top priorities for Spain’s policymakers in ‘White Book’

The book is a new guide to improving Parkinson's treatment in Spain

READ MORE
MJFox and Coldplay

Perspectives

Guitar hero: Michael J Fox joins Coldplay to perform Back to the Future scene

Parkinson’s hero turns guitar hero (again) for one night

READ MORE